Literature DB >> 17566052

How common is repeat sudden infant death syndrome?

C J Bacon1, D B M Hall, T J Stephenson, M J Campbell.   

Abstract

Recurrence of sudden infant death syndrome (SIDS) is rare but may give rise to confusion and controversy because of the differential diagnoses of familial disease or covert homicide. We examine eight studies of recurrent SIDS published in English since 1970. These studies reported relative risks of recurrence, as compared with the population or with controls, ranging from 1.7 to 10.1. We assess the validity of the studies by three main criteria: accuracy of ascertainment, adequacy of investigation and matching of controls. We found that all the studies failed to meet these criteria, and we think that their flaws would have resulted mainly in overestimation of recurrence risk. We conclude that, although an increase in risk is probable on theoretical grounds, this risk cannot be quantified from the available evidence. We suggest that professionals should be cautious in their pronouncements on the chances of recurrence, and that parents who have lost a baby to SIDS can, with the exception of particularly vulnerable families, be reassured that the risk of recurrence is small.

Entities:  

Mesh:

Year:  2007        PMID: 17566052     DOI: 10.1136/adc.2006.113969

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  2 in total

1.  Child neurology: a case illustrating the role of imaging in evaluation of sudden infant death.

Authors:  Sarah M Kranick; Jaya Ganesh; Curtis R Coughlin; Daniel J Licht
Journal:  Neurology       Date:  2009-09-15       Impact factor: 9.910

Review 2.  Role of congenital long-QT syndrome in unexplained sudden infant death: proposal for an electrocardiographic screening in relatives.

Authors:  Alban-Elouen Baruteau; Julien Baruteau; Ryad Joomye; Raphael Martins; Frédéric Treguer; Remi Baruteau; Jean-Claude Daubert; Philippe Mabo; Michel Roussey
Journal:  Eur J Pediatr       Date:  2009-03-06       Impact factor: 3.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.